Výsledky vyhledávání - "Sanjeev Balu"

Akademický článek

Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment

Autor: Steven R. Feldman, Annie Guerin, Marjolaine Gauthier-Loiselle, Ami J. Claxton, Nisha C. Hazra, Yan Meng, Kirsten Gallant, Sanjeev Balu

Publikováno v: Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)

AbstractPurpose: Evidence on treatment preferences of patients with moderate-to-severe atopic dermatitis (AD) in the United States (US) is limited and an assessment of treatment preferences in this group is warranted.Materials and methods: An online

Externí odkaz: https://doaj.org/article/1e5c0852cac242acba347e58337d0eb0

Zobrazit plný text záznamu

Abstract P1-18-18: Real-world natural history data among patients with PIK3CA-mutant and PIK3CA-wild-type advanced breast cancer

Autor: Pedram Razavi, Rohan C Parikh, Barbara Acevedo, Abigail Hitchens, Mehnaj Ahmed, Anton Safonov, Emanuela Ferraro, Komal Jhaveri, Michelle Sidel, Stacey Simmons, Mark Robson, Sarat Chandarlapaty, Sanjeev Balu

Publikováno v: Cancer Research. 82:P1-18

Background: Oncogenic mutations involving PIK3CA gene (PI3Kα) are observed in over 40% of patients with hormone receptor-positive (HR+) advanced breast cancer (ABC). Clinical efficacy of PI3K inhibition was demonstrated in a recent trial, but data o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6eb3d9d9d649ab635eb8503581b5c76e
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-18

Zobrazit plný text záznamu

Abstract P5-13-16: A real-world assessment of PIK3CA testing and alpelisib treatment patterns among metastatic breast cancer patients in a community oncology setting

Autor: Joyce O'Shaughnessy, Steven Paulson, Lorraine Brisbin, James Lindsey, Anna Williford, Monica Lisi, Rohan C. Parikh, Stacey Simmons, Sanjeev Balu

Publikováno v: Cancer Research. 82:P5-13

Background: Alpelisib (PIQRAY®) in combination with fulvestrant was approved by the US- FDA in May of 2019 for patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) PIK3CA mutant advanced or meta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::53c5c6f23573ed0ce2b1350720dcdc20
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-16

Zobrazit plný text záznamu

Abstract PS10-48: Cardiovascular (CV) risk profile in patients with estrogen receptor (ER) positive HER2 negative advanced breast cancer (ABC): A retrospective cohort study (CAREB)

Autor: Gloria Broadwater, Susan Dent, Gretchen Kimmick, Kevin C. Oeffinger, Michel G. Khouri, Sanjeev Balu, Terry Hyslop

Publikováno v: Cancer Research. 81:PS10-48

Background: CDK 4/6 inhibitors in patients (pts) with HR+/HER2- ABC has led to significant improvements in clinical outcomes, however our understanding of the impact of these treatments on CV health is unknown. Gains in overall survival should not be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e8e3342d9c088c96b6bd457785d8989
https://doi.org/10.1158/1538-7445.sabcs20-ps10-48

Zobrazit plný text záznamu

Evaluation of access to care issues in patients with breast cancer

Autor: Chisom Kanu, Carolyn M. Brown, Sanjeev Balu, Kristin M. Richards, Barbara L. McAneny, Yogesh Vohra, Rahul Sasane, Laura Stevens

Publikováno v: Journal of Medical Economics. 24:38-45

System-level efforts have been deployed to improve oncology care and access while reducing utilization and costs. Understanding the nature of access to care from the perspective of patients themselves is an unmet need. This study examined access to c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::498c0186f5909130f0ea4284f8884889
https://doi.org/10.1080/13696998.2020.1858580

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání